Indicatori di risposta subottimale all’infliximab

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. Am J Gastroenterol. 2010 May;105(5):1133-9. Epub 2010 Feb 9. OBJECTIVES: Human anti-chimeric antibodies (HACAs) and subtherapeutic infliximab concentrations are associated with decreased duration of response.…

Review sistematica sull’intolleranza al lattosio

Systematic review: effective management strategies for lactose intolerance.Shaukat A, Levitt MD, Taylor BC, MacDonald R, Shamliyan TA, Kane RL, Wilt TJ. Ann Intern Med. 2010 Jun 15;152(12):797-803. BACKGROUND: Lactose intolerance resulting in gastrointestinal symptoms is a common health concern. Diagnosis and management of this condition remain unclear. PURPOSE: To assess the maximum tolerable dose of…

Meta-analisi sull’effetto del placebo nella MRGE

Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease.Cremonini F, Ziogas D, Chang HY, Kokkotou E, Kelly J, Conboy L, Kaptchuk TJ, Lembo AJ. Aliment Pharmacol Ther. 2010 Mar 26. [Epub ahead of print]  Background: Gastro-oesophageal reflux disease (GERD) is a common chronic condition effectively treated in most patients with proton pump inhibitors (PPI) or…

PPI e rischio fratture: non tutte le ossa sono uguali…..

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Arch Intern Med. 2010 May 10;170(9):765-71. BACKGROUND: Proton pump inhibitor (PPI) medications have been inconsistently shown to be associated with osteoporotic…